Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease

RSC Advances

Volumn 2, Issue 12, 2012, Pages 5008-5033

  Laurent, Sophie ^a   Ejtehadi, Mohammad Reza ^b   Rezaei, Meisam ^b   Kehoe, Patrick G ^c   Mahmoudi, Morteza ^d,e  

^a UNIVERSITY OF MONS   (Belgium)

^b SHARIF UNIVERSITY OF TECHNOLOGY   (Iran)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER'S DISEASE; BIOLOGICAL MARKERS; CONVENTIONAL THEORY; EARLY DIAGNOSIS; HEALTH SERVICES; NANOSCIENCE AND NANOTECHNOLOGIES; SCIENTIFIC COMMUNITY; THERANOSTIC AGENTS;

DIAGNOSIS; NEURODEGENERATIVE DISEASES;

NANOSCIENCE;

EID: 84865155590     PISSN: None     EISSN: 20462069     Source Type: Journal    
DOI: 10.1039/c2ra01374f     Document Type: Review

References (187)

1. C. M. Dobson Protein Folding and Misfolding Nature 2003 426 884 890
2. C. J. Frederickson J.-Y. Koh A. I. Bush The neurobiology of zinc in health and disease Nat. Rev. Neurosci. 2005 6 449 462
3. L. Mucke Neuroscience: Alzheimer's disease Nature 2009 461 895 897
4. F. M. LaFerla Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease Nat. Rev. Neurosci. 2002 3 862 872
5. M. Gough C. Parr-Sturgess E. Parkin Zinc Metalloproteinases and Amyloid Beta-Peptide Metabolism: The Positive Side of Proteolysis in Alzheimer's Disease Biochem. Res. Int. 2011 721463 13
6. M. Mahmoudi, P. Stroeve, A. S. Milani and A. Arbab, Superparamagnetic iron oxide nanoparticles for biomedical applications, Nova Science Publishers, Inc., New York, 2010
7. R. Von Bernhardi J. Eugenín Alzheimer's disease: Redox dysregulation as a common denominator for diverse pathogenic mechanisms Antioxidants and Redox Signaling 2012 16 974 1031
8. B. L. Plassman K. M. Langa G. G. Fisher S. G. Heeringa D. R. Weir M. B. Ofstedal J. R. Burke M. D. Hurd G. G. Potter W. L. Rodgers D. C. Steffens R. J. Willis R. B. Wallace Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study Neuroepidemiology 2007 29 125 132
9. L. E. Hebert P. A. Scherr J. L. Bienias D. A. Bennett D. A. Evans Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch. Neurol. 2003 60 1119 1122
10. M. Heron D. L. Hoyert S. L. Murphy J. Xu K. D. Kochanek B. Tejada-Vera Deaths: final data for 2006. National Vital Statistics Report 2009 57 1 134
11. C. P. Ferri M. Prince C. Brayne H. Brodaty L. Fratiglioni M. Ganguli K. Hall K. Hasegawa H. Hendrie Y. Huang A. Jorm C. Mathers P. R. Menezes E. Rimmer M. Scazufca Global prevalence of dementia: a Delphi consensus study Lancet 2005 366 2112 7
12. P. A. Broderick, D. N. Rahni and E. H. Kolodny, Bioimaging in neurodegeneration, Humana Press, New York, 2005
13. D. Soffer Cerebral amyloid angiopathy - a disease or age-related condition Isr Med Assoc J. 2006 8 803 806
14. R. C. Petersen Mild cognitive impairment: transition between aging and Alzheimer's disease Neurologia (Barcelona, Spain) 2000 15 93 101
15. S. Russell H Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? Neurobiol. Aging 2007 28 1465 1480
16. J. L. Cummings R. Doody C. Clark Disease-modifying therapies for Alzheimer disease Neurology 2007 69 1622 1634
17. H. Braak E. Braak Neuropathological staging of Alzheimer-related changes Acta Neuropathol. 1991 82 239 59
18. P. M. Thompson K. M. Hayashi R. A. Dutton M.-C. Chiang A. D. Leow E. R. Sowell G. De Zubicaray J. T. Becker O. L. Lopez H. J. Aizenstein A. W. Toga Tracking Alzheimer's Disease Ann. N. Y. Acad. Sci. 2007 1097 183 214
19. K. Sambamurti N. Greig D. Lahiri Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease NeuroMol. Med. 2002 1 1 31
20. H. A. Lashuel D. Hartley B. M. Petre T. Walz P. T. Lansbury Neurodegenerative disease: Amyloid pores from pathogenic mutations Nature 2002 418 291 291
21. L. Haataja T. Gurlo C. J. Huang P. C. Butler Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer Hypothesis Endocr. Rev. 2008 29 303 316
22. B. Sommer Alzheimer's disease and the amyloid cascade hypothesis: ten years on Curr. Opin. Pharmacol. 2002 2 87 92
23. S. S. Sisodia Beta-amyloid precursor protein cleavage by a membrane-bound protease Proc. Natl. Acad. Sci. U. S. A. 1992 89 6075 6079
24. A. L. Brunkan A. M. Goate Presenilin function and γ-secretase activity J. Neurochem. 2005 93 769 792
25. L. Bertram M. B. McQueen K. Mullin D. Blacker R. E. Tanzi Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database Nat. Genet. 2007 39 17 23
26. J. D. Sipe, Amyloid proteins - the beta sheet conformation and disease, Wiley-VCH, Weinheim, Germany, 2005
27. 42/40 Ratio PLoS One 2009 4 e7893
28. A. P. Carvalho L. C. Gursky R. T. Rosa A. U. M. Rymovicz P. M. S. Campelo A. M. T. Grégio C. Y. Koga-Ito L. P. Samaranayake E. A. R. Rosa Non-steroidal anti-inflammatory drugs may modulate the protease activity of Candida albicans Microb. Pathog. 2010 49 315 322
29. L.-M. Munter P. Voigt A. Harmeier D. Kaden K. E. Gottschalk C. Weise R. Pipkorn M. Schaefer D. Langosch G. Multhaup GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of A[beta]42 EMBO J. 2007 26 1702 1712
30. I. Dewachter L. Ris S. Croes P. Borghgraef H. Devijver T. Voets B. Nilius E. Godaux F. Van Leuven Modulation of synaptic plasticity and Tau phosphorylation by wild-type and mutant presenilin1. Neurobiol. Aging 2008 29 639 652
31. D. Walsh I. Klyubin J. V. Fadeeva W. K. Cullen R. Anwyl M. S. Wolfe M. J. Rowan D. J. Selkoe Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo Nature 2002 416 535 539
32. D. M. Walsh D. M. Hartley Y. Kusumoto Y. Fezoui M. Margaret M. M. Condron A. Lomakin G. B. Benedek D. J. Selkoe D. B. Teplow Amyloid betaprotein fibrillogenesis. Structure and biological activity of protofibrillar intermediates J. Biol. Chem. 1999 274 25945 25952
33. D. M. Walsh D. J. Selkoe Abeta Oligomers a decade of discovery J. Neurochem. 2007 101 1172 1184
34. M. Ramakrishnan K. K. Kandimalla T. M. Wengenack K. G. Howell J. F. Poduslo Biochemistry 2009 48 10405 10415
35. K. Brännström A. Öhman A. Olofsson PLoS One 2010 6 e25157
36. M. C. Montalto G. Farrar C. T. Hehir Fibrillar and Oligomeric β-Amyloid as Distinct Local Biomarkers for Alzheimer's Disease Ann. N. Y. Acad. Sci. 2007 1097 239 258
37. Y. Fezoui D. M. Hartley J. D. Harper R. Khurana D. M. Walsh M. M. Condron D. J. Selkoe P. T. Lansbury A. L. Fink D. B. Teplow An improved method of preparing the amyloid β-protein for fibrillogenesis and neurotoxicity experiments Amyloid 2000 7 166 178
38. T. B. David, Preparation of Amyloid β-Protein for Structural and Functional Studies, in Methods in Enzymology, ed., K. Indu, and, W. Ronald, Academic Press, 2006, vol. 413, pp 20-33
39. K. Wiesehan S. A. Funke M. Fries D. Willbold Purification of recombinantly expressed and cytotoxic human amyloid-beta peptide 1-42 J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2007 856 229 233
40. H. Wei Z. Xie Anesthesia, calcium homeostasis and Alzheimer's disease Curr. Alzheimer Res. 2009 6 30 35
41. A. M. D'Ursi M. R. Armenante R. Guerrini S. Salvadori G. Sorrentino D. Picone Solution Structure of Amyloid β-Peptide (25-35) in Different Media J. Med. Chem. 2004 47 4231 4238
42. T. Kohno K. Kobayashi T. Maeda K. Sato A. Takashima Three-Dimensional Structures of the Amyloid β Peptide (25-35) in Membrane-Mimicking Environment Biochemistry 1996 35 16094 16104
43. J. Suh W. S. Chei Metal complexes as artificial proteases: toward catalytic drugs Curr. Opin. Chem. Biol. 2008 12 207 213
44. J. D. Harper P. T. Lansbury Models of Amyloid Seeding in Alzheimer's Disease and Scrapie: Mechanistic Truths and Physiological Consequences of the Time-Dependent Solubility of Amyloid Proteins Annu. Rev. Biochem. 1997 66 385 407
45. O. Ashur-Fabian Y. Segal-Ruder E. Skutelsky D. E. Brenneman R. A. Steingart E. Giladi I. Gozes Peptides 2003 24 1413 1423
46. T. Lührs C. Ritter M. Adrian D. Riek-Loher B. Bohrmann H. Döbeli D. Schubert R. Riek 3D structure of Alzheimer's amyloid-β(1-42) fibrils Proc. Natl. Acad. Sci. U. S. A. 2005 102 17342 17347
47. L. O. Tjernberg A. Tjernberg N. Bark Y. Shi B. P. Ruzsicska Z. Bu J. Thyberg D. J. Callaway Assembling amyloid fibrils from designed structures containing a significant amyloid beta-peptide fragment Biochem J. 2002 366 343 351
48. J. Zheng H. Jang B. Ma C.-J. Tsai R. Nussinov Modeling the Alzheimer A 17-42 Fibril Architecture: Tight Intermolecular Sheet-Sheet Association and Intramolecular Hydrated Cavities Biophys. J. 2007 93 3046 3057
49. J. Van Dorpe L. Smeijers I. Dewachter D. Nuyens K. Spittaels C. Van den Haute M. Mercken D. Moechars I. Laenen C. Kuiperi K. Bruynseels I. Tesseur R. Loos H. Vanderstichele F. Checler R. Sciot F. Van Leuven Prominent Cerebral Amyloid Angiopathy in Transgenic Mice Overexpressing the London Mutant of Human APP in Neurons Am. J. Pathol. 2000 157 1283 1298
50. C. S. Atwood R. D. Moir X. Huang R. C. Scarpa N. M. E. Bacarra D. M. Romano M. A. Hartshorn R. E. Tanzi A. I. Bush Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis J. Biol. Chem. 1998 273 12817 12826
51. N. C. Inestrosa, J. P. Sagal and M. Colombres, Acetylcholinesterase interaction with Alzheimer amyloid β Alzheimer's disease, ed., J. R. Harris, and, F. Fahrenholz, Springer, US, 2005, vol. 38, pp 299-317
52. C. Morgan M. P. Bugueño J. Garrido N. C. Inestrosa Laminin affects polymerization, depolymerization and neurotoxicity of Aβ peptide Peptides 2002 23 1229 1240
53. L. Guilloreau L. Damian Y. Coppel H. Mazarguil M. Winterhalter P. Faller Structural and thermodynamical properties of Cu(ii) amyloid-β 16/28 complexes associated with Alzheimer's disease J. Biol. Inorg. Chem. 2006 11 1024 1038
54. L. Hou M. G. Zagorski NMR Reveals Anomalous Copper(II) Binding to the Amyloid Aβ Peptide of Alzheimer's Disease J. Am. Chem. Soc. 2006 128 9260 9261
55. M. L. Steven Iron deposits in multiple sclerosis and Alzheimer's disease brains Brain Res. 1997 760 298 303
56. C. Glabe and A. I. Bush, Aβ Structure and aggregation Alzheimer's disease. ed. S. S., Sisodia, and R. E., Tanzi, Springer, US, 2007, pp 113-131
57. A. C. Miu O. Benga Aluminum and Alzheimer's disease: A new look Journal of Alzheimer's Disease 2006 10 179 201
58. S. L. Sabo A. F. Ikin J. D. Buxbaum P. Greengard The Amyloid Precursor Protein and Its Regulatory Protein, FE65, in Growth Cones and Synapses In Vitro and In Vivo The Journal of Neuroscience 2003 23 5407 5415
59. J. C. Palmer S. Baig P. G. Kehoe S. Love Endothelin-Converting Enzyme-2 Is Increased in Alzheimer's Disease and Up-Regulated by Aβ Am. J. Pathol. 2009 175 262 270
60. I. Dewachter J. Van Dorpe L. Smeijers M. Gilis C. Kuipéri I. Laenen N. Caluwaerts D. Moechars F. Checler H. Vanderstichele F. Van Leuven Aging Increased Amyloid Peptide and Caused Amyloid Plaques in Brain of Old APP/V717I Transgenic Mice by a Different Mechanism than Mutant Presenilin1 The Journal of Neuroscience 2000 20 6452 6458
61. J. S. Miners Z. Van Helmond K. Chalmers G. Wilcock S. Love P. G. Kehoe Decreased Expression and Activity of Neprilysin in Alzheimer Disease Are Associated With Cerebral Amyloid Angiopathy J. Neuropathol. Exp. Neurol. 2006 65 1012 1021
62. Y. C. Kudva H. J. Hiddinga P. C. Butler C. S. Mueske N. L. Eberhardt Small heat shock proteins inhibit in vitro Aβ1-42 amyloidogenesis FEBS Lett. 1997 416 117 121
63. W. E. Van Nostrand M Porter Plasmin Cleavage of the Amyloid β-Protein: Alteration of Secondary Structure and Stimulation of Tissue Plasminogen Activator Activity Biochemistry 1999 38 11570 11576
64. C. Reitz F. J. A. van Rooij H. D. Soares M. P. M. de Maat A. Hofman J. C. M. Witteman M. M. B. Breteler Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: The Rotterdam Study Neurobiol. Aging 2010 31 715 718
65. A. Majumdar H. Chung G. Dolios R. Wang N. Asamoah P. Lobel F. R. Maxfield Degradation of fibrillar forms of Alzheimer's amyloid β-peptide by macrophages Neurobiol. Aging 2008 29 707 715
66. R. Deane B. V. Zlokovic Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease Curr. Alzheimer Res. 2007 4 191 197
67. F. Licastro S. Pedrini L. Caputo G. Annoni L. J. Davis C. Ferri V. Casadei L. M. E. Grimaldi Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J. Neuroimmunol. 2000 103 97 102
68. S. Craft E. Peskind M. W. Schwartz G. D. Schellenberg M. Raskind D. Porte Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease Neurology 1998 50 164 168
69. R. Mayeux L. S. Honig M.-X. Tang J. Manly Y. Stern N. Schupf P. D. Mehta Plasma Aβ40 and Aβ42 and Alzheimer's disease Neurology 2003 61 1185 1190
70. S. Lorenzl D. S. Albers N. Relkin T. Ngyuen S. L. Hilgenberg J. Chirichigno M. E. Cudkowicz M. F. Beal Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease Neurochem. Int. 2003 43 191 196
71. R. Clarke A. D. Smith K. A. Jobst H. Refsum L. Sutton P. M. Ueland Folate, Vitamin B12, and Serum Total Homocysteine Levels in Confirmed Alzheimer Disease Arch. Neurol. 1998 55 1449 1455
72. P. D. Mehta T. Pirttila B. A. Patrick M. Barshatzky S. P. Mehta Amyloid β protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease Neurosci. Lett. 2001 304 102 106
73. T. Nishikimi Y. Saito K. Kitamura T. Ishimitsu T. Eto K. Kangawa H. Matsuo T. Omae H. Matsuoka Increased plasma levels of adrenomedullin in patients with heart failure J. Am. Coll. Cardiol. 1995 26 1424 1431
74. R. Deane S. Du Yan R. K. Submamaryan B. LaRue S. Jovanovic E. Hogg D. Welch L. Manness C. Lin J. Yu H. Zhu J. Ghiso B. Frangione A. Stern A. M. Schmidt D. L. Armstrong B. Arnold B. Liliensiek P. Nawroth F. Hofman M. Kindy D. Stern B. Zlokovic RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain Nat. Med. 2003 9 907 913
75. V. Calabrese R. Lodi C. Tonon V. D'Agata M. Sapienza G. Scapagnini A. Mangiameli G. Pennisi A. M. G. Stella D. A. Butterfield Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia J. Neurol. Sci. 2005 233 145 162
76. I. G. Onyango S. M. Khan Oxidative Stress, Mitochondrial Dysfunction, and Stress Signaling in Alzheimers Disease Curr. Alzheimer Res. 2006 3 339 349
77. P.-C. Suen K. Wu E. S. Levine H. T. J. Mount J.-L. Xu S.-Y. Lin I. B. Black Brain-derived neurotrophic factor rapidly enhances phosphorylation of the postsynaptic N-methyl-d-aspartate receptor subunit 1 Proc. Natl. Acad. Sci. U. S. A. 1997 94 8191 8195
78. E. S. Levine J. E. Kolb Brain-derived neurotrophic factor increases activity of NR2B-containing N-methyl-d-aspartate receptors in excised patches from hippocampal neurons J. Neurosci. Res. 2000 62 357 362
79. A. M. Marini S. J. Rabin R. H. Lipsky I. Mocchetti Activity-dependent Release of Brain-derived Neurotrophic Factor Underlies the Neuroprotective Effect of N-Methyl-d-aspartate J. Biol. Chem. 1998 273 29394 29399
80. S. Vaynman Z. Ying F. Gomez-Pinilla Interplay between brain-derived neurotrophic factor and signal transduction modulators in the regulation of the effects of exercise on synaptic-plasticity Neuroscience 2003 122 647 657
81. T. Tanaka H. Saito N. Matsuki Inhibition of GABAA Synaptic Responses by Brain-Derived Neurotrophic Factor (BDNF) in Rat Hippocampus The Journal of Neuroscience 1997 17 2959 2966
82. R. H. Lipsky K. Xu D. Zhu C. Kelly A. Terhakopian A. Novelli A. M. Marini Nuclear factor κB is a critical determinant in N-methyl-d-aspartate receptor-mediated neuroprotection J. Neurochem. 2001 78 254 264
83. B. E. Bisel K. M. Henkins K. D. Parfitt Alzheimer Amyloid β-Peptide A-β25-35 Blocks Adenylate Cyclase-Mediated Forms of Hippocampal Long-Term Potentiation Ann. N. Y. Acad. Sci. 2007 1097 58 63
84. K. J. De Vos A. J. Grierson S. Ackerley C. C. J. Miller Role of Axonal Transport in Neurodegenerative Diseases Annu. Rev. Neurosci. 2008 31 151 173
85. J. Grutzendler K. Helmin J. Tsai W.-B. Gan Various Dendritic Abnormalities Are Associated with Fibrillar Amyloid Deposits in Alzheimer's Disease Ann. N. Y. Acad. Sci. 2007 1097 30 39
86. O. Wirths J. Weis R. Kayed T. C. Saido T. A. Bayer Age-dependent axonal degeneration in an Alzheimer mouse model Neurobiol. Aging 2007 28 1689 1699
87. M. P. Cuajungco K. Y. Fagét Zinc takes the center stage: its paradoxical role in Alzheimer's disease Brain Res. Rev. 2003 41 44 56
88. M. A. Smith P. L. R. Harris L. M. Sayre G. Perry Iron accumulation in Alzheimer disease is a source of redox-generated free radicals Proc. Natl. Acad. Sci. U. S. A. 1997 94 9866 9868
89. X. Huang M. P. Cuajungco C. S. Atwood R. D. Moir R. E. Tanzi A. I. Bush Alzheimer's Disease, β-Amyloid Protein and Zinc The Journal of Nutrition 2000 130 1488S 1492S
90. M. A. Smith K. Hirai K. Hsiao M. A. Pappolla P. L. R. Harris S. L. Siedlak M. Tabaton G. Perry Amyloid-β Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress J. Neurochem. 1998 70 2212 2215
91. K. R. Brunden J. Q. Trojanowski V. M. Y. Lee Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies Nat. Rev. Drug Discovery 2009 8 783 793
92. M.-S. Yu K.-C. Suen N.-S. Kwok K.-F. So J. Hugon R. Chuen-Chung Chang Beta-amyloid peptides induces neuronal apoptosis via a mechanism independent of unfolded protein responses Apoptosis 2006 11 687 700
93. K. A. Roth Caspases, Apoptosis, and Alzheimer Disease: Causation, Correlation, and Confusion Journal of Neuropathology & Experimental Neurology 2001 60 829 838
94. S. D. Yan X. Chen J. Fu M. Chen H. Zhu A. Roher T. Slattery L. Zhao M. Nagashima J. Morser A. Migheli P. Nawroth D. Stern A. M. Schmidt RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996 382 685 691
95. J. Rogers L.-F. Lue Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease Neurochem. Int. 39 333 340
96. L. Meda P. Baron G. Scarlato Glial activation in Alzheimer's disease: the role of Aβ and its associated proteins Neurobiol. Aging 2001 22 885 893
97. J. G. Sheng R. A. Jones X. Q. Zhou J. M. McGinness L. J. Van Eldik R. E. Mrak W. S. T. Griffin Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation Neurochem. Int. 2001 39 341 348
98. D. Terwel D. Muyllaert I. Dewachter P. Borghgraef S. Croes H. Devijver F. Van Leuven Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice. Am. J. Pathol. 2008 172 786 798
99. F. G. De Felice D. Wu M. P. Lambert S. J. Fernandez P. T. Velasco P. N. Lacor E. H. Bigio J. Jerecic P. J. Acton P. J. Shughrue E. Chen-Dodson G. G. Kinney W. L. Klein Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers Neurobiol. Aging 2008 29 1334 1347
100. M. Rapoport A. Ferreira PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons J. Neurochem. 2000 74 125 133
101. B. P. Tseng K. N. Green J. L. Chan M. Blurton-Jones F. M. LaFerla Aβ inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging 2008 29 1607 1618
102. M. Rapoport H. N. Dawson L. I. Binder M. P. Vitek A. Ferreira Tau is essential to β-amyloid-induced neurotoxicity Proc. Natl. Acad. Sci. U. S. A. 2002 99 6364 6369
103. E. D. Roberson K. Scearce-Levie J. J. Palop F. Yan I. H. Cheng T. Wu H. Gerstein G.-Q. Yu L. Mucke Reducing Endogenous Tau Ameliorates Amyloid β-Induced Deficits in an Alzheimer's Disease Mouse Model Science 2007 316 750 754
104. N. F. Bence R. M. Sampat R. R. Kopito Impairment of the Ubiquitin-Proteasome System by Protein Aggregation Science 2001 292 1552 1555
105. J. Lowe H. McDermott M. Landon R. J. Mayer K. D. Wilkinson Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases J. Pathol. 1990 161 153 160
106. A. Ciechanover P. Brundin The Ubiquitin Proteasome System in Neurodegenerative Diseases: Sometimes the Chicken, Sometimes the Egg Neuron 2003 40 427 446
107. J. Lowe R. J. Mayer M. Landon Ubiquitin in Neurodegenerative Diseases Brain Pathol. 1993 3 55 65
108. D. E. Ehrnhoefer B. K. Y. Wong M. R. Hayden Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development Nat. Rev. Drug Discovery 2011 10 853 867
109. E. Karran M. Mercken B. D. Strooper The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics Nat. Rev. Drug Discovery 2011 10 698 712
110. E. D. Roberson L. Mucke 100 Years and Counting: Prospects for Defeating Alzheimer's Disease Science 2006 314 781 784
111. D. L. Brody D. M. Holtzman Active and Passive Immunotherapy for Neurodegenerative Disorders Annu. Rev. Neurosci. 2008 31 175 193
112. E. M. Sigurdsson E. Knudsen A. Asuni C. Fitzer-Attas D. Sage D. Quartermain F. Goni B. Frangione T. Wisniewski An Attenuated Immune Response Is Sufficient to Enhance Cognition in an Alzheimer's Disease Mouse Model Immunized with Amyloid-β Derivatives J. Neurosci. 2004 24 6277 6282
113. L. O. Tjernberg J. Näslund F. Lindqvist J. Johansson A. R. Karlström J. Thyberg L. Terenius C. Nordstedt Arrest of β-Amyloid Fibril Formation by a Pentapeptide Ligand J. Biol. Chem. 1996 271 8545 8548
114. L. O. Tjernberg C. Lilliehöök D. J. E. Callaway J. Näslund S. Hahne J. Thyberg L. Terenius C. Nordstedt Controlling Amyloid β-Peptide Fibril Formation with Protease-stable Ligands J. Biol. Chem. 1997 272 12601 12605
115. K.-I. Watanabe K. Nakamura S. Akikusa T. Okada M. Kodaka T. Konakahara H. Okuno Inhibitors of Fibril Formation and Cytotoxicity of β-Amyloid Peptide Composed of KLVFF Recognition Element and Flexible Hydrophilic Disrupting Element Biochem. Biophys. Res. Commun. 2002 290 121 124
116. J. E. Gestwicki G. R. Crabtree I. A. Graef Harnessing Chaperones to Generate Small-Molecule Inhibitors of Amyloid β Aggregation Science 2004 306 865 869
117. L. Rajendran A. Schneider G. Schlechtingen S. Weidlich J. Ries T. Braxmeier P. Schwille J. B. Schulz C. Schroeder M. Simons G. Jennings H.-J. Knölker K. Simons Efficient Inhibition of the Alzheimer's Disease β-Secretase by Membrane Targeting Science 2008 320 520 523
118. N. F. Schor What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us Ann. Neurol. 2011 69 237 239
119. R. Etcheberrigaray M. Tan I. Dewachter C. Kuipéri I. Van der Auwera S. Wera L. Qiao B. Bank T. J. Nelson A. P. Kozikowski F. Van Leuven D. L. Alkon Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice Proc. Natl. Acad. Sci. U. S. A. 2004 101 11141 11146
120. M. Garcia-Alloza L. A. Borrelli A. Rozkalne B. T. Hyman B. J. Bacskai Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model J. Neurochem. 2007 102 1095 1104
121. M. Sano K. L. Bell D. Galasko J. E. Galvin R. G. Thomas C. H. van Dyck P. S. Aisen A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease Neurology 2011 77 556 563
122. B. Marchetti M. P. Abbracchio To be or not to be (inflamed) - is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol. Sci. 2005 26 517 525
123. A. H. Nagahara D. A. Merrill G. Coppola S. Tsukada B. E. Schroeder G. M. Shaked L. Wang A. Blesch A. Kim J. M. Conner E. Rockenstein M. V. Chao E. H. Koo D. Geschwind E. Masliah A. A. Chiba M. H. Tuszynski Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease Nat. Med. 2009 15 331 337
124. R. S. Doody S. I. Gavrilova M. Sano R. G. Thomas P. S. Aisen S. O. Bachurin L. Seely D. Hung Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study Lancet 2008 372 207 215
125. M. N. Lopez R. A. Charter B. Mostafavi L. P. Nibut W. E. Smith Psychometric Properties of the Folstein Mini-Mental State Examination Assessment 2005 12 137 144
126. B. Vellas S. Andrieu C. Sampaio G. Wilcock Disease-modifying trials in Alzheimer's disease: a European task force consensus Lancet Neurol. 2007 6 56 62
127. H. Hampel R. Frank K. Broich S. J. Teipel R. G. Katz J. Hardy K. Herholz A. L. W. Bokde F. Jessen Y. C. Hoessler W. R. Sanhai H. Zetterberg J. Woodcock K. Blennow Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat. Rev. Drug Discovery 2010 9 560 574
128. M. Citron Alzheimer's disease: strategies for disease modification Nat. Rev. Drug Discovery 2010 9 387 398
129. K. A. Jellinger B. Janetzky J. Attems E. Kienzl Alzheimer Review Series: Biomarkers for early diagnosis of Alzheimer disease: 'Alzheimer Associated gene' - a new blood biomarker? J. Cell. Mol. Med. 2008 12 1094 1117
130. I. Blasko K. Jellinger G. Kemmler W. Krampla S. Jungwirth I. Wichart K. H. Tragl P. Fischer Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine Neurobiol. Aging 2008 29 1 11
131. A. M. Fagan C. M. Roe C. Xiong M. A. Mintun J. C. Morris D. M. Holtzman Cerebrospinal Fluid tau/beta-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults Arch. Neurol. 2007 64 343 349
132. N. S. M. Schoonenboom W. M. van der Flier M. A. Blankenstein F. H. Bouwman G. J. Van Kamp F. Barkhof P. Scheltens CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease Neurobiol. Aging 2008 29 669 675
133. F. H. Bouwman N. S. M. Schoonenboom N. A. Verwey E. J. van Elk A. Kok M. A. Blankenstein P. Scheltens W. M. van der Flier CSF biomarker levels in early and late onset Alzheimer's disease Neurobiol. Aging 2009 30 1895 1901
134. J.-M. Lee K. Blennow N. Andreasen O. Laterza V. Modur J. Olander F. Gao M. Ohlendorf J. H. Ladenson The Brain Injury Biomarker VLP-1 Is Increased in the Cerebrospinal Fluid of Alzheimer Disease Patients Clin. Chem. 2008 54 1617 1623
135. P. Montuschi P. J. Barnes L. J. Roberts Isoprostanes: markers and mediators of oxidative stress FASEB J. 2004 18 1791 1800
136. L. Fei S. Perrett Effect of Nanoparticles on Protein Folding and fibrillogenesis Int. J. Mol. Sci. 2009 10 646 655
137. R. C. Triulzi Q. Dai J. Zou R. M. Leblanc Q. Gu J. Orbulescu Q. Huo Photothermal ablation of amyloid aggregates by gold nanoparticles Colloids Surf., B 2008 63 200 208
138. T. Takahashi H. Mihara Acc. Chem. Res. 2008 41 1309
139. I. Klyubin D. M. Walsh C. A. Lemere W. K. Cullen G. M. Shankar Y. Betts E. T. Spooner L. Jiang R. Anwyl D. J. Selkoe M. J. Rowan Nat. Med. 2005 11 556
140. Y. Bae N. H. Kim M. Kim K. Y. Lee S. W. Han J. Am. Chem. Soc. 2008 130 5432
141. G. A. DeVries Y. Hu B. Long B. T. Neltner O. Uzun B. H. Wunsch F. Stellacci Science 2007 315 358
142. M. Klokkenburg A. J. Houtepen R. Koole J. W. J. de Folter B. M. Ern E. van Faassen D. Vanmaekelbergh Nano Lett. 2007 7 2931
143. K. S. Cho D. V. Talapin W. Gaschler C. B. Murray J. Am. Chem. Soc. 2005 127 7140
144. S. Yoo M. Yang J. R. Brender V. Subramanian K. Sun N. E. Joo S. H. Jeong A. Ramamoorthy N. A. Kotov Inhibition of Amyloid Peptide Fibrillation by Inorganic Nanoparticles: Functional Similarities with Proteins Angew. Chem., Int. Ed. 2011 50 5110 5115
145. Y. Xia Nat. Mater. 2008 7 758
146. I. Lynch K. A. Dawson Nano Today 2008 3 40
147. M. Sarikaya C. Tamerler A. K. Y. Jen K. Schulten F. Baneyx Nat. Mater. 2003 2 577
148. S. Linse C. Cabaleiro-Lago W. F. Xue I. Lynch S. Lindman E. Thulin S. E. Radford K. A. Dawson Proc. Natl. Acad. Sci. U. S. A. 2007 104 8691
149. S. Auer A. Trovato M. A. Vendruscolo PLoS Comput. Biol. 2009 5 e1000458
150. W. H. Wu X. Sun Y. P. Yu J. Hu L. Zhao Q. Liu Y. F. Zhao Y. M. Li Biochem. Biophys. Res. Commun. 2008 373 315
151. A. S Pai I. Rubinstein H. Onyuksel Peptides 2006 7 2858 2866
152. J. E. Kim M. Lee Biochem. Biophys. Res. Commun. 2003 303 576 579
153. S. Rocha A. F. Thunemann C. Pereira Mdo M. Coelho H. Mohwald G. Brezesinski Biophys. Chem. 2008 137 35 42
154. C. Cabaleiro-Lago F. Quinlan-Pluck I. Lynch S. Lindman A. M. Minogue E. Thulin D. M. Walsh K. A. Dawson S. Linse J. Am. Chem. Soc. 2008 130 15437 15443
155. J. N. Anker W. P. Hall O. Lyandres N. C. Shah J. Zhao R. P. Van Duyne Biosensing with plasmonic nanosensors Nat. Mater. 2008 7 442 453
156. A. Relini C. Canale S. De Stefano R. Rolandi S. Giorgetti M. Stoppini A. Rossi F. Fogolari A. Corazza G. Esposito A Gliozzi V. Bellotti J. Biol. Chem. 2006 281 16521
157. S. L. Myers S. Jones T. R. Jahn I. J. Morten G. A. Tennent E. W. Hewitt S. E. Radford Biochemistry 2006 45 2311
158. V. Sluzky J. A. Tamada A. M. Klibanov R. Langer Proc. Natl. Acad. Sci. U. S. A. 1991 88 9377
159. J. R. Lu S. Perumal E. T. Powers J. W. Kelly J. R. P. Webster J. Penfold J. Am. Chem. Soc. 2003 125 3751
160. E. T. Powers J. W. Kelly J. Am. Chem. Soc. 2001 123 775
161. K. Ikeda T. Okada S. I. Sawada K. Akiyoshi K. Matsuzaki FEBS Lett. 2006 580 6587
162. L. Xiao D. Zhao W. H. Chan M. M. F. Choi H. W. Li Biomaterials 2010 31 91
163. C. Cabaleiro-Lago F. Quinlan-Pluck I. Lynch K. A. Dawson S. Linse ACS Chem. Neurosci. 2010 1 279 287
164. G. Thakur M. Micic Y. Yang W. Li D. Movia S. Giordani H. Zhang R. M. Leblanc International Journal of Alzheimer's Disease 2011
165. J. Milojevic A. Raditsis G. Melacini Biophys. J. 2009 97 2585
166. J. Milojevic V. Esposito R. Das G. Melacini J. Am. Chem. Soc. 2007 129 4282
167. B. Bohrmann L. Tjernberg P. Kuner S. Poli B. Levet-Trafit J. N. Slund G. Richards W. Huber H. Dbeli C. Nordstedt J. Biol. Chem. 1999 274 15990
168. H. Skaat G. Shafir S. Margel J. Nanopart. Res. 2011 13 3521 3534
169. W. L. Jorgensen D. S. Maxwell J. Tirado-Rives Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 1996 118 11225 11236
170. H. J. C. Berendsen J. P. M. Postma W. F. van Gunsteren A. Dinola J. R. Haak Molecular dynamics with coupling to an external bat J. Chem. Phys. 1984 81 3684 3690
171. T. Darden D. York L. Pedersen Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems J. Chem. Phys. 1993 98 10089 10092
172. B. Hess H. Bekker H. J. C. Berendsen J. G. E. M. Fraaije LINCS: A Linear Constraint Solver for molecular simulations J. Comput. Chem. 1997 18 1463 1472
173. M. A. Lovell J. D. Robertson W. J. Teesdale J. L. Campbell W. R. Markesbery Copper, iron and zinc in Alzheimer's disease senile plaques J. Neurol. Sci. 1998 158 47 52
174. G. Faa M. Lisci M. P. Caria R. Ambu R. Sciot V. M. Nurchi R. Silvagni A. Diaz G. Crisponi Brain copper, iron, magnesium, zinc, calcium, sulfur and phosphorus storage in Wilson's disease J. Trace Elem. Med. Biol. 2001 15 155 160
175. K. S. Jagannatha Rao R. V. Rao P. Shanmugavelu R. B. Menon Trace elements in Alzheimer's disease brain: A new hypothesis Alzheimer's Reports 1999 2 241 246
176. K. S. J. Rao P. Shanmugavelu S. K. Shankar R. P. R. Devi R. V. Rao S. P. R. B. Menon Trace elements in the cerebrospinal fluid in Alzheimer's disease Alzheimer's Reports 1999 2 333 338
177. J. Kornhuber K. W. Lange P. Kruzik W. D. Rausch E. Gabriel K. Jellinger P. Riederer Iron, copper, zinc, magnesium, and calcium in postmortem brain tissue from schizophrenic patients Biol. Psychiatry 1994 36 31 34
178. T. M. Michel S. Frangou D. Thiemeyer S. Camara J. Jecel K. Nara A. Brunklaus R. Zoechling P. Riederer Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder - a postmortem study Psychiatry Res. 2007 151 145 150
179. T. Lech J. K. Sadlik Zinc in Postmortem Body Tissues and Fluids Biol. Trace Elem. Res. 2011 142 11 17
180. M. Mahmoudi S. Laurent M. A. Shokrgozar M. Hosseinkhani Toxicity Evaluations of Superparamagnetic Iron Oxide Nanoparticles: Cell Vision Versus Physicochemical Properties of Nanoparticles ACS Nano 2011 5 7263 7276
181. 2+ signaling in human neuroblastoma (SH-SY5Y) cells J. Neurochem. 2009 111 1192 1201
182. 2+ release following oxidative stress in neuronal cells involves type 2 inositol-1,4,5-trisphosphate receptors Neuroscience 2011 175 281 291
183. 2+-dependent apoptosis induced by amyloid B-peptide in human neuroblastoma IMR32 cells Journal of Neurochemistry 2008 107 1070 1082
184. 2+ signaling in human endothelial and smooth muscle cells in pre-eclampsia. Antioxid. Redox Signaling 2009 11 1149 1163
185. G. Maulthaup H. Mechler C. L. Masters Characterization of the high affinity heparin binding site of the Alzheimer's disease βA4 amyloid precursor protein (APP) and its enhancement by zinc(ii) J. Mol. Recognit. 1995 8 247 257
186. M.-S. García-Ayllón O. Cauli M.-X. Silveyra R. Rodrigo A. Candela A. Compañ R. Jover M. Pérez-Mateo S. Martínez V. Felipo J. Sáez-Valero Brain cholinergic impairment in liver failure Brain 2008 131 2946 2956
187. F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci and M. Kivipelto, Aging Research Center, Karolinska Institutet, Stockholm, Sweden, PubMed.gov, http://www.ncbi.nlm.nih.gov/pubmed/20610346, Erratum in Lancet Neurol., 2011, 10 (6), 501